Compound Evidence File
#EC-2026-0311
Orforglipron
Filed under Oral Tablets. The bureau holds 142 laboratory returns for this compound from 59 distinct subjects. Scores below are per-subject aggregates; open a subject row for the underlying evidence.
Cross-Index
Subjects Shipping This Compound
59 SUBJECTS| Subject | Grade | Samples | Mean | Min | Max | First seen | Last seen |
|---|---|---|---|---|---|---|---|
| HomopeptideCASE #VI-2026-0760 | A | 6 | 10.0 | 9.9 | 10.0 | 24 May 2026 | 24 May 2026 |
| Tianjin Finder Chemical TFCCASE #VI-2026-0693 | A | 4 | 10.0 | 9.9 | 10.0 | 14 Nov 2025 | 16 Apr 2026 |
| Shanghai ERP BiotechnologyCASE #VI-2026-0936 | A | 4 | 10.0 | 9.9 | 10.0 | 15 Mar 2026 | 3 Jul 2026 |
| Kerui PeptidesCASE #VI-2026-0626 | A | 4 | 10.0 | 9.9 | 10.0 | 20 Jan 2026 | 2 Jul 2026 |
| Mokemei BiotechnologyCASE #VI-2026-0540 | A | 4 | 10.0 | 9.9 | 10.0 | 26 Nov 2025 | 14 Jul 2026 |
| Shanghai Wibson BiotechnologyCASE #VI-2026-0379 | A | 4 | 10.0 | 10.0 | 10.0 | 12 Mar 2026 | 22 Apr 2026 |
| PolyPeptide GroupCASE #VI-2026-0143 | A | 4 | 10.0 | 9.9 | 10.0 | 7 Dec 2025 | 7 Aug 2026 |
| BachemCASE #VI-2026-0314 | A | 3 | 10.0 | 10.0 | 10.0 | 1 Nov 2025 | 24 May 2026 |
| Shanghai Sigma AudleyCASE #VI-2026-0505 | A | 3 | 10.0 | 9.9 | 10.0 | 24 Mar 2026 | 8 Jul 2026 |
| GenScript PeptidesCASE #VI-2026-0860 | A | 2 | 10.0 | 10.0 | 10.0 | 16 Feb 2026 | 6 May 2026 |
| QYAOBIOCASE #VI-2026-0861 | A | 4 | 9.9 | 9.9 | 10.0 | 18 Feb 2026 | 3 Jul 2026 |
| Chinese Peptide CompanyCASE #VI-2026-0184 | A | 4 | 9.9 | 9.9 | 9.9 | 8 Mar 2026 | 27 Jun 2026 |
| Hybio PharmaceuticalCASE #VI-2026-0065 | A | 4 | 9.9 | 9.9 | 10.0 | 6 Feb 2026 | 17 Jul 2026 |
| AsymchemCASE #VI-2026-0091 | A | 4 | 9.9 | 9.9 | 10.0 | 19 Mar 2026 | 28 Jun 2026 |
| JEEP PeptidesCASE #VI-2026-0457 | A | 3 | 9.9 | 9.9 | 10.0 | 25 Mar 2026 | 3 Jun 2026 |
| Flourishglobal PeptideCASE #VI-2026-0630 | A | 3 | 9.9 | 9.9 | 10.0 | 3 Apr 2026 | 22 Jun 2026 |
| WuXi TIDESCASE #VI-2026-0335 | A | 3 | 9.9 | 9.9 | 10.0 | 12 Nov 2025 | 10 May 2026 |
| Sigma-AldrichCASE #VI-2026-0829 | A | 3 | 9.9 | 9.9 | 10.0 | 9 Jan 2026 | 4 Aug 2026 |
| Thermo Fisher ScientificCASE #VI-2026-0142 | A | 3 | 9.9 | 9.9 | 10.0 | 14 Jun 2026 | 8 Jul 2026 |
| AmbioPharmCASE #VI-2026-0177 | A | 3 | 9.9 | 9.9 | 10.0 | 27 Apr 2026 | 17 Aug 2026 |
| Sangon BioCASE #VI-2026-0671 | A | 2 | 9.9 | 9.9 | 10.0 | 17 Feb 2026 | 3 May 2026 |
| Hubei JianxiangCASE #VI-2026-0048 | A | 2 | 9.9 | 9.9 | 9.9 | 20 Jan 2026 | 2 Mar 2026 |
| SinoPepCASE #VI-2026-0387 | A | 2 | 9.9 | 9.9 | 10.0 | 14 Feb 2026 | 4 Mar 2026 |
| CellupepCASE #VI-2026-0888 | X | 1 | 9.3 | 9.3 | 9.3 | 21 May 2025 | 21 May 2025 |
| Laicuinuo LCNCASE #VI-2026-0223 | X | 1 | 9.1 | 9.1 | 9.1 | 11 Jun 2025 | 11 Jun 2025 |
| Qingdao Sigma Chemical QSCCASE #VI-2026-0538 | A | 6 | 8.9 | 7.8 | 10.0 | 21 May 2026 | 21 May 2026 |
| Wuhan Wansheng Bio (WWB)CASE #VI-2026-0594 | A | 3 | 8.9 | 7.9 | 9.9 | 25 May 2026 | 25 May 2026 |
| NUPEPS PeptidesCASE #VI-2026-0896 | X | 1 | 8.9 | 8.9 | 8.9 | 2 Jul 2025 | 2 Jul 2025 |
| Glbiochem (Shanghai)CASE #VI-2026-0704 | A | 2 | 8.4 | 8.0 | 8.8 | 21 May 2026 | 21 May 2026 |
| Nantong Guangyuan Chemical GYCCASE #VI-2026-0284 | A | 3 | 8.2 | 6.6 | 9.3 | 24 May 2026 | 24 May 2026 |
| Zztai PeptideCASE #VI-2026-0192 | C | 2 | 8.1 | 8.0 | 8.1 | 16 Mar 2025 | 21 May 2026 |
| Dankang BioHealthCASE #VI-2026-0775 | X | 1 | 8.0 | 8.0 | 8.0 | 13 Jun 2025 | 13 Jun 2025 |
| Yongkang Nuoao Trading CoCASE #VI-2026-0646 | X | 1 | 8.0 | 8.0 | 8.0 | 21 May 2025 | 21 May 2025 |
| Shandong Aishi BiotechnologyCASE #VI-2026-0308 | X | 3 | 7.7 | 7.2 | 8.5 | 25 Apr 2025 | 26 Jan 2026 |
| EHZ PeptidesCASE #VI-2026-0296 | X | 1 | 7.7 | 7.7 | 7.7 | 2 Jul 2025 | 2 Jul 2025 |
| Shanghai Sigma Audley SSACASE #VI-2026-0486 | A | 3 | 7.6 | 6.0 | 9.3 | 21 May 2026 | 21 May 2026 |
| TCICASE #VI-2026-0650 | X | 1 | 7.3 | 7.3 | 7.3 | 9 Jun 2025 | 9 Jun 2025 |
| Shaanxi Dideu MedichemCASE #VI-2026-0499 | X | 1 | 7.1 | 7.1 | 7.1 | 6 May 2025 | 6 May 2025 |
| Peptide HavenCASE #VI-2026-0898 | X | 1 | 6.9 | 6.9 | 6.9 | 21 May 2025 | 21 May 2025 |
| SRY LabsCASE #VI-2026-0657 | X | 9 | 6.8 | 5.2 | 7.9 | 20 Jun 2025 | 21 May 2026 |
| Amino AmigosCASE #VI-2026-0061 | X | 3 | 6.8 | 5.6 | 7.8 | 21 May 2025 | 17 May 2026 |
| Mix PeptidesCASE #VI-2026-0699 | X | 2 | 6.8 | 6.7 | 7.0 | 3 Jul 2025 | 26 Jan 2026 |
| Alpha-GenCASE #VI-2026-0905 | X | 1 | 6.8 | 6.8 | 6.8 | 13 Jun 2025 | 13 Jun 2025 |
| ScienceCASE #VI-2026-0636 | X | 1 | 6.8 | 6.8 | 6.8 | 13 Feb 2025 | 13 Feb 2025 |
| Peptides 4 ResearchCASE #VI-2026-0511 | X | 1 | 6.8 | 6.8 | 6.8 | 21 May 2025 | 21 May 2025 |
| Zen PeptidesCASE #VI-2026-0940 | X | 1 | 6.7 | 6.7 | 6.7 | 3 Jul 2025 | 3 Jul 2025 |
| Huayi BiotechnologyCASE #VI-2026-0243 | X | 1 | 6.4 | 6.4 | 6.4 | 25 Apr 2025 | 25 Apr 2025 |
| Quenna PMQCASE #VI-2026-0415 | X | 1 | 6.3 | 6.3 | 6.3 | 28 Mar 2025 | 28 Mar 2025 |
| TSC Top Supplements ChinaCASE #VI-2026-0523 | X | 2 | 5.8 | 5.4 | 6.3 | 24 Apr 2025 | 26 Jan 2026 |
| Amino AsylumCASE #VI-2026-0828 | X | 1 | 5.4 | 5.4 | 5.4 | 3 Jul 2025 | 3 Jul 2025 |
| Kerisite Shenzhen InternationalCASE #VI-2026-0315 | X | 1 | 5.1 | 5.1 | 5.1 | 24 Apr 2025 | 24 Apr 2025 |
| Qingdao Hongshengda TradingCASE #VI-2026-0334 | X | 1 | 5.0 | 5.0 | 5.0 | 14 Jan 2025 | 14 Jan 2025 |
| Explicit SarmsCASE #VI-2026-0017 | X | 1 | 2.4 | 2.4 | 2.4 | 3 Jul 2025 | 3 Jul 2025 |
| WllyBIOCASE #VI-2026-0470 | X | 1 | 2.1 | 2.1 | 2.1 | 6 May 2025 | 6 May 2025 |
| DeuschemCASE #VI-2026-0004 | X | 2 | 1.5 | 1.3 | 1.7 | 21 May 2025 | 24 May 2026 |
| Advanced Technology and IndustrialCASE #VI-2026-0133 | X | 1 | 1.5 | 1.5 | 1.5 | 3 Jun 2025 | 3 Jun 2025 |
| Guangzhou Yuao TradingCASE #VI-2026-0787 | X | 1 | 1.2 | 1.2 | 1.2 | 7 May 2025 | 7 May 2025 |
| Wuhan Newtop BiotechCASE #VI-2026-0676 | X | 1 | 0.0 | 0.0 | 0.0 | 25 Apr 2025 | 25 Apr 2025 |
| LOOKBiotechCASE #VI-2026-0807 | X | 1 | 0.0 | 0.0 | 0.0 | 13 Feb 2025 | 13 Feb 2025 |
Open any subject to view the batch-level evidence for Orforglipron alone.